Nanna Therapeutics
Disease-modifying Medicines
Disease-modifying Medicines
Nanna Therapeutics is a United Kingdom-based biotech company founded in 2012. It is a subsidiary of Astellas, a Japanese global pharmaceutical company, and is part of the Mitobridge Division, which is a US- and UK-based research engine of Astellas. The company focuses on developing small-molecule therapeutics for various diseases, with a primary focus on mitochondria-related research. Nanna Therapeutics works alongside Mitobridge, a Boston-based biotech acquired by Astellas in 2018. In 2020, Nanna Therapeutics was acquired by Astellas. The company received a £829.89K grant investment from Innovate UK in April 2019. Nanna Therapeutics' mission is to develop disease-modifying medicines, leveraging its expertise in biotechnology and healthcare. More information about the company can be found on its website, www.nannatherapeutics.com. Nanna Therapeutics' strategic alliance with Astellas and its focus on mitochondrial research positions it as a promising player in the biotech industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | £829.89K | 1 |
|
09 Apr 2019 |
| Venture Round | Unknown | 1 | New Wave Ventures | 10 Dec 2014 |
No recent news or press coverage available for Nanna Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
